Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Proceedings of the National Academy of Sciences of the United States of America

• Publication date

  1997-04-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1073/PNAS.94.7.3330PMID 9096393PMCID PMC20369
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genetic Mechanisms in Multiple Endocrine Neoplasia Type 2

  2013cited by this paper
• Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations

  1997cited by this paper
• Signalling by the W/Kit receptor tyrosine kinase is negatively regulated in vivo by the protein tyrosine phosphatase Shp1

  1996cited by this paper
• GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a Novel Receptor for GDNF

  1996cited by this paper
• Characterization of a multicomponent receptor for GDNF

  1996cited by this paper
• GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-alpha, a novel receptor for GDNF.

  1996cited by this paper
• Defects in enteric innervation and kidney development in mice lacking GDNF

  1996cited by this paper
• Functional receptor for GDNF encoded by the c-ret proto-oncogene

  1996cited by this paper
• GDNF signalling through the Ret receptor tyrosine kinase

  1996cited by this paper
• Renal agenesis and the absence of enteric neurons in mice lacking GDNF

  1996cited by this paper
• Mechanisms of carcinogenesis and the mutant mouse.

  1996cited by this paper
• The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.

  1996cited by this paper
• Renal and neuronal abnormalities in mice lacking GDNF

  1996cited by this paper
• Germline and somatic mutations in an oncogene: RET mutations in inherited medullary thyroid carcinoma.

  1996cited by this paper
• Mutation analysis of the c-mos proto-oncogene and the endothelin-B receptor gene in medullary thyroid carcinoma and phaeochromocytoma.

  1996cited by this paper
• Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET.

  1995cited by this paper
• RET activation by germline MEN2A and MEN2B mutations.

  1995cited by this paper
• A novel point mutation in the tyrosine kinase domain of the RET proto-oncogene in sporadic medullary thyroid carcinoma and in a family with FMTC.

  1995cited by this paper
• Detection of a germline mutation at codon 918 of the RET proto-oncogene in French MEN 2B families

  1995cited by this paper
• RET gene and its implications for cancer.

  1995cited by this paper
• Catalytic specificity of protein-tyrosine kinases is critical for selective signalling

  1995cited by this paper
• Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B

  1995cited by this paper
• Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features.

  1995cited by this paper
• Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations

  1995cited by this paper
• RET mutations in exons 13 and 14 of FMTC patients.

  1995cited by this paper
• Tyrosine kinase inhibition: an approach to drug development.

  1995cited by this paper
• Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret

  1994cited by this paper
• Retinoblastoma and p53 tumour suppressor gene protein expression in carcinomas of the thyroid gland

  1994cited by this paper
• Point mutation within the tyrosine kinase domain of the RET proto-oncogene in multiple endocrine neoplasia type 2B and related sporadic tumours.

  1994cited by this paper
• A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma

  1994cited by this paper
• Cooperative tumorigenic effects of germline mutations in Rb and p53

  1994cited by this paper
• Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B.

  1994cited by this paper
• Heterozygous Rb-1 delta 20/+mice are predisposed to tumors of the pituitary gland with a nearly complete penetrance.

  1994cited by this paper
• Specific mutations of the RET proto-oncogene are related to disease phenotype in MEN 2A and FMTC

  1994cited by this paper
• RET proto-oncogene mutations in French MEN 2A and FMTC families.

  1994cited by this paper
• Mos stimulates MAP kinase in Xenopus oocytes and activates a MAP kinase kinase in vitro

  1993cited by this paper
• Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC.

  1993cited by this paper
• Expression of the c-ret proto-oncogene during mouse embryogenesis.

  1993cited by this paper
• Genetic events in tumour initiation and progression in multiple endocrine neoplasia type 2

  1993cited by this paper
• Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A

  1993cited by this paper
• Pheochromocytomas and C-cell thyroid neoplasms in transgenic c-mos mice: a model for the human multiple endocrine neoplasia type 2 syndrome.

  1992cited by this paper
• SV40 T antigen transforms calcitonin cells of the thyroid but not CGRP-containing neurons in transgenic mice.

  1991cited by this paper
• Characterization of ret proto-oncogene mRNAs encoding two isoforms of the protein product in a human neuroblastoma cell line.

  1990cited by this paper
• Early calcitonin hypersecretion and C cell hyperplasia in rats with high incidence of C cell tumors (Wag/Rij).

  1989cited by this paper
• Human ret proto-oncogene mapped to chromosome 10q11.2.

  1989cited by this paper
• Abnormal expression of the MOS proto-oncogene in human thyroid medullary carcinoma.

  1988cited by this paper
• Multistep migration of calcitonin cell precursors during ontogeny of the mouse pharynx.

  1979cited by this paper

• Patient-Derived in Vitro Models Reveal Insights into Medullary Thyroid Cancer Microenvironment and Resistance to Tyrosine Kinase Inhibitors.

  2026cites this paper
• Thyroid C-Cell Biology and Oncogenic Transformation.

  2025cites this paper
• Genetically engineered mouse models of head and neck cancers

  2023cites this paper
• Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database

  2022cites this paper
• Preclinical Models of Neuroendocrine Neoplasia

  2022cites this paper
• Comprehensive Assessment of Copy Number Alterations Uncovers Recurrent AIFM3 and DLK1 Copy Gain in Medullary Thyroid Carcinoma

  2021cites this paper
• Mouse models in endocrine tumors.

  2019cites this paper
• Medullary thyroid carcinoma beyond surgery: advances, challenges, and perspectives.

  2019cites this paper
• Medullary Thyroid Cancer

  2019cites this paper
• Mice conditionally expressing RET(C618F) mutation display C cell hyperplasia and hyperganglionosis of the enteric nervous system

  2019influential citation
• Non-mammalian models of multiple endocrine neoplasia type 2.

  2018cites this paper
• Rodent models of pheochromocytoma, parallels in rodent and human tumorigenesis

  2018cites this paper
• Transcriptional landscape of a RETC634Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR1 transcriptional program in the development of multiple endocrine neoplasia type 2A-associated cancers.

  2018cites this paper
• Multiple Endocrine Neoplasia Syndromes

  2018cites this paper
• Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes

  2018cites this paper
• Animal models of medullary thyroid cancer: state of the art and view to the future.

  2017cites this paper
• Transcriptional landscape of a RETC 634 Y-mutated iPSC and its CRISPR-corrected isogenic control reveals the putative role of EGR 1 transcriptional program in the development of multiple endocrine neoplasia type 2 A-associated cancers

  2017cites this paper
• Familial thyroid carcinoma: the road less traveled in thyroid pathology – an update

  2017cites this paper
• Selective Ablation of Tumor Suppressors in Parafollicular C Cells Elicits Medullary Thyroid Carcinoma*

  2017influential citation
• Animal models of multiple endocrine neoplasia.

  2016cites this paper
• Generation of an induced pluripotent stem cell line from a patient with hereditary multiple endocrine neoplasia 2A (MEN2A) syndrome with RET mutation.

  2016cites this paper
• ATF4 Targets RET for Degradation and Is a Candidate Tumor Suppressor Gene in Medullary Thyroid Cancer.

  2016cites this paper
• Molecular Mechanisms of Disease: The RET Proto-oncogene

  2016cites this paper
• Mouse models of thyroid cancer: A 2015 update.

  2016cites this paper
• Mouse models of medullary thyroid cancer and developing new targeted therapies

  2016cites this paper
• On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited

  2016cites this paper
• Classical point mutations of RET, BRAF and RAS oncogenes are not shared in papillary and medullary thyroid cancer occurring simultaneously in the same gland

  2016cites this paper
• Mouse Models of Receptor Tyrosine Kinases

  2015cites this paper
• Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease

  2015cites this paper
• Thyroid C-Cell Biology and Oncogenic Transformation.

  2015cites this paper
• Familial syndromes associated with neuroendocrine tumours

  2015cites this paper
• Mouse Models of Thyroid Neoplasia: Insights into Thyroid Pathophysiology

  2014cites this paper
• Identification of two novel RET kinase inhibitors through MCR-based drug discovery: design, synthesis and evaluation.

  2014cites this paper
• Medullary Thyroid Carcinoma: a 25-Year Perspective

  2014cites this paper
• Evolutionary Dynamics Unifies Carcinogenesis and Cancer Therapy

  2014cites this paper
• Ret Oncogene and Thyroid Carcinoma

  2014cites this paper
• Exome sequencing reveals mutant genes with low penetrance involved in MEN2A-associated tumorigenesis.

  2014cites this paper
• Exome sequencing reveals mutant genes with low penetrance involved in MEN 2 A-associated tumorigenesis

  2014cites this paper
• Chapter 58 – Endocrine System

  2013cites this paper
• In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

  2013cites this paper
• GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation.

  2012cites this paper
• Co-registration of fluorescence diffuse optical tomography (fDOT) with Positron emission tomography (PET) and development of multi-angle fDOT

  2012influential citation
• Evolutionary dynamics of carcinogenesis and why targeted therapy does not work

  2012cites this paper
• Mouse models for inherited endocrine and metabolic disorders.

  2011cites this paper
• Pharmacologie moléculaire du sunitinib et du vandetanib, deux inhibiteurs d’activité kinase, dans le cancer médullaire de la thyroïde

  2011cites this paper
• New Targeted Therapies for Thyroid Cancer

  2011cites this paper
• Thyroid Cancer: Molecular and Modern Advances

  2011cites this paper
• Development of RET kinase inhibitors for targeted cancer therapy.

  2011cites this paper
• Chromogranin A as potential target for immunotherapy of malignant pheochromocytoma.

  2011cites this paper
• Sprouty1 is a candidate tumor suppressor gene in medullary thyroid carcinoma

  2011influential citation
• Best Practice & Research Clinical Endocrinology & Metabolism

  2010cites this paper
• Advances in Cellular Therapy for the Treatment of Thyroid Cancer

  2010cites this paper
• Recent Developments in the Molecular Biology of the Thyroid

  2010cites this paper
• [Multiple endocrine neoplasia: genetic aspects].

  2010cites this paper
• Transmissible Genes Induced Chromosome-type Aberrations in the Lymphocytes of Multiple Endocrine Neoplasia Type 1 and Type 2A (MEN1 and MEN2A) Patients

  2010cites this paper
• In vivo identification of neural stem cells in the enteric nervous system

  2010cites this paper
• The evolving field of tyrosine kinase inhibitors in the treatment of endocrine tumors.

  2010cites this paper
• Carcinogenesis and therapeutic strategies in thyroid cancer.

  2010cites this paper
• Mouse models of endocrine tumours.

  2010cites this paper
• Néoplasies endocriniennes multiples, aspects génétiques.

  2010cites this paper
• Mouse Models of Endocrine Tumors

  2010cites this paper
• Thyroid Stem Cells and Cancer

  2009cites this paper
• Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.

  2009cites this paper
• Animal models of hyperfunctioning parathyroid diseases for drug development

  2009cites this paper
• Modeling Thyroid Cancer in the Mouse

  2009cites this paper
• Constitutive RET tyrosine kinase activation in hereditary medullary thyroid cancer: clinical opportunities

  2009cites this paper
• Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma

  2009cites this paper
• Chromogranin A as Potential Tumour Antigen in Pheochromocytoma

  2009cites this paper
• Chapter 7 – Thyroid and Parathyroid Glands

  2009cites this paper
• PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[18F]F-L-DOPA

  2009influential citation
• Dendritic Cell Vaccination with Xenogenic Polypeptide Hormone Induces Tumor Rejection in Neuroendocrine Cancer

  2008cites this paper
• Amino acid-modified calcitonin immunization induces tumor epitope-specific immunity in a transgenic mouse model for medullary thyroid carcinoma.

  2008influential citation
• Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study

  2008cites this paper
• Genetic Alterations in Thyroid Cancer: The Role of Mouse Models

  2007cites this paper
• Medullary thyroid cancer: monitoring and therapy.

  2007cites this paper
• Endocrine Neoplasia Type 2 Syndrome Mutations in the Multiple ret The Phenotypes Associated with Updated Version

  2007cites this paper
• Genotype-Phenotype Based Surgical Concept of Hereditary Medullary Thyroid Carcinoma

  2007cites this paper
• Néoplasies endocriniennes multiples de type 2

  2007cites this paper
• Sodium/iodide symporter regulation by oncogenes in the mammary gland and thyroid gland using mouse models

  2007cites this paper
• Apoptotic cell death induction and angiogenesis inhibition in large established medullary thyroid carcinoma xenografts by Ret inhibitor RPI-1.

  2006cites this paper
• Current concepts in RET-related genetics, signaling and therapeutics.

  2006cites this paper
• Current concepts in RET-related genetics and signalling

  2006cites this paper
• Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer.

  2006cites this paper
• Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.

  2006cites this paper
• MOLECULAR CHARACTERISATION OF RET TYROSINE KINASE SIGNALLING

  2005cites this paper
• A Drosophila Model of Multiple Endocrine Neoplasia Type 2

  2005cites this paper
• [Genetics of endocrine tumours].

  2005cites this paper
• RET tyrosine kinase signaling in development and cancer.

  2005cites this paper
• Génétique des tumeurs endocrines

  2005cites this paper
• Neoplasia endócrina múltipla tipo 2

  2005cites this paper
• 23. RET ACTIVATION IN MEDULLARY CARCINOMAS

  2005cites this paper
• Hereditary hormone excess: genes, molecular pathways, and syndromes.

  2005cites this paper
• Molecular genetics of multiple endocrine neoplasia types 1 and 2

  2005cites this paper
• [Multiple endocrine neoplasia type 2].

  2005cites this paper
• Molecular genetics of multiple endocrine neoplasia types 1 and 2

  2005cites this paper
• A human yeast artificial chromosome containing the multiple endocrine neoplasia type 2B Ret mutation does not induce medullary thyroid carcinoma but does support the growth of kidneys and partially rescues enteric nervous system development in Ret-deficient mice.

  2005cites this paper
• Medullary thyroid carcinoma arises in the absence of prolactin signaling.

  2005cites this paper
• The genetic basis of pheochromocytoma.

  2004cites this paper
• Molecular events in follicular thyroid tumors.

  2004cites this paper
• Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma.

  2004cites this paper